Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...100101102103104105106107108109110...858859»
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Trial completion, Trial completion date, Metastases:  Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC). (clinicaltrials.gov) -  Jan 16, 2024   
    P4,  N=100, Completed, 
    Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025 Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Dec 2023
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Enrollment change, Trial termination, Minimal residual disease:  ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT (clinicaltrials.gov) -  Jan 16, 2024   
    P2,  N=3, Terminated, 
    Trial completion date: Jul 2028 --> Jan 2024 N=32 --> 3 | Recruiting --> Terminated; Terminated by Amgen Limited
  • ||||||||||  Kineret (anakinra) / SOBI, Actimmune (interferon gamma-1 b) / Clinigen, Amgen
    Trial completion date, Trial primary completion date:  ImmunoSep: Personalized Immunotherapy in Sepsis (clinicaltrials.gov) -  Jan 15, 2024   
    P2,  N=280, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Jul 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Jan 2025
  • ||||||||||  Review, Journal, Metastases:  New developments and standard of care in the management of advanced gastric cancer. (Pubmed Central) -  Jan 15, 2024   
    Based on phase 2 studies, trastuzumab-deruxtecan was approved in 2022 by the EMA for HER2-positive pretreated patients. This agent is currently evaluated in phase 3 study (DESTINY-Gastric04 trial), as are several other anti-HER2 (zanidatamab, margetuximab, tucatinib), immune checkpoint inhibitors, or targeted therapies (anti-FGFR2b).
  • ||||||||||  Vectibix (panitumumab) / Amgen, Takeda, Lumakras (sotorasib) / Amgen
    Journal:  Combating KRASG12C Inhibitor Resistance. (Pubmed Central) -  Jan 15, 2024   
    Findings from the phase III CodeBreaK 300 trial indicate that adding the EGFR inhibitor panitumumab to sotorasib bests standard care for chemorefractory KRASG12C colorectal cancer. Joint SHP2 blockade is another approach that shows signs of activity in reversing acquired KRASG12C inhibitor resistance, according to preliminary phase I data.
  • ||||||||||  xaluritamig (AMG 509) / Amgen
    P1 data, Journal, Metastases:  Xaluritamig, a STEAP1  (Pubmed Central) -  Jan 15, 2024   
    Xaluritamig demonstrated encouraging responses (PSA and RECIST) compared with historical established treatments for patients with late-line mCRPC. This study provides proof of concept for T-cell engagers as a potential treatment for prostate cancer, validates STEAP1 as a target, and supports further clinical investigation of xaluritamig in prostate cancer.
  • ||||||||||  oprozomib (ONX 0912) / Amgen, marizomib (NPI-0052) / Triphase Accelerator Corporation, BMS, Ninlaro (ixazomib) / Takeda
    Review, Journal:  Proteasome inhibitors as anticancer agents. (Pubmed Central) -  Jan 15, 2024   
    The extension of proteasome inhibitors for the treatment of solid tumors, and their ability to pass the blood-brain barrier open new possibilities for treating central nervous system cancers. However, managing adverse effects, particularly those affecting the central nervous system, remains a critical consideration and a strategic 'working on' aspect for the near future.
  • ||||||||||  Kineret (anakinra) / SOBI, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
    Journal:  Choice and switch of biologic drugs in juvenile idiopathic arthritis. (Pubmed Central) -  Jan 15, 2024   
    Good responses were obtained in most of our patients with a reliable profile. However, studies on larger patient groups are needed to clarify these results.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Ezharmia (valemetostat) / Daiichi Sankyo
    Preclinical, Journal:  Characterization of a Preclinical In Vitro Model Derived from a SMARCA4-Mutated Sinonasal Teratocarcinosarcoma. (Pubmed Central) -  Jan 15, 2024   
    Focusing on mutated SMARCA4 as the therapeutic target, growth inhibition assays showed a strong response to the CDK4/6 inhibitor palbociclib, but much less to the EZH1/2 inhibitor valemetostat. In conclusion, cell line TCS627 carries both histologic and genetic features characteristic of TCS and is a valuable model for both basic research and preclinical testing of new therapeutic options for treatment of TCS patients.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Journal:  Sotorasib in KRAS mutated lung cancer - Authors' reply. (Pubmed Central) -  Jan 14, 2024   
    Our findings were able to stratify OC patients with high risk, unfavorable prognosis and variant treatment sensitivity, thus improving clinical outcomes for OC patients. No abstract available
  • ||||||||||  Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
    Journal:  Effect of Loratadine for Pegfilgrastim-Induced Bone Pain. (Pubmed Central) -  Jan 12, 2024   
    Randomized controlled trials are needed to adequately assess the effectiveness of all three medication options. Because little is known about optimal use of any of these medications for pegfilgrastim-induced bone pain, it is also important to identify the optimal time to initiate treatment and ideal treatment duration.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Retrospective data, Journal:  Surgical Strategy for Recurrent Giant Cell Tumor in the Thoracolumbar Spine. (Pubmed Central) -  Jan 12, 2024   
    TES with wide/marginal margin should be offered to patients with RGCT whenever feasible, given its long-term benefits in local control and symptom alleviation. Additionally, patients with lower Ki67 index and application of denosumab tend to have a better prognosis.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Trial completion date, Trial primary completion date:  Blina-CELL: Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) -  Jan 11, 2024   
    P2,  N=45, Active, not recruiting, 
    Trial completion date: Apr 2024 --> Oct 2024 | Initiation date: Oct 2023 --> Jan 2024 Trial completion date: Jan 2026 --> Jul 2024 | Trial primary completion date: May 2025 --> Feb 2024
  • ||||||||||  Bimzelx (bimekizumab) / UCB
    Journal:  Bimekizumab (Bimzelx) for psoriasis. (Pubmed Central) -  Jan 11, 2024   
    Trial completion date: Jan 2026 --> Jul 2024 | Trial primary completion date: May 2025 --> Feb 2024 No abstract available
  • ||||||||||  Review, Journal:  The Role of IL-23 Inhibitors in Crohn's Disease. (Pubmed Central) -  Jan 11, 2024   
    Risankizumab, mirikizumab, and guselkumab are specific IL-23p19 antagonists tested for the treatment of Crohn's disease (CD)...Trials with guselkumab and mirikizumab are currently ongoing, with promising preliminary efficacy and safety results. In this review, we provide a summary of the current knowledge about selective IL-23 inhibitors, focusing on their positioning in the therapeutic algorithm of patients with moderate to severe CD.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
    Review, Journal:  Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies. (Pubmed Central) -  Jan 11, 2024   
    Further triumphs were not seen for almost 10 years, until the approval of initially regorafenib and shortly after trifluridine/tipiracil...Here, we review the most recent clinical data for late-line treatment options in mCRC, focusing on randomized trials if available. We include recommendations for options in unselected patients and therapies that should only be offered in patients with distinct tumor profiles (e.g., BRAF mutations, KRAS G12C mutations, HER2 amplification, deficient MMR, or NTRK gene fusions).